Intel, Qualcomm lobby against U.S. gov’s ban on supplying to Huawei
By Akshay Kedari  Date: 2019-06-17

Intel, Qualcomm lobby against U.S. gov’s ban on supplying to Huawei

The ban will apparently result in catastrophic consequences for the U.S chipmakers since Huawei is one of their major customers

Reports suggest that Intel, Qualcomm and other American chip suppliers for Huawei, are quietly persuading the U.S. government to ease the ban on sales to the Chinese tech giant. Executives from top chipmakers in the U.S. attended a meeting with the commerce department recently to discuss a response to the U.S administration placing Huawei in the blacklist.

The ban reportedly forbids suppliers in the U.S. to sell chips to Huawei without acquiring a special approval, due to national security concerns, as pointed out by the government.

Apparently, Huawei spent $70 billion in buying components in 2018 out of which approximately $11 billion dollar was sent to firms in the U.S. which included Intel, Micron Technology Inc. and Qualcomm.

Citing sources familiar with the situation, the chip makers argued that security concerns associated with Huawei’s 5G networking gear would not be posed by the Chinese firm’s products like computer servers and smartphones, as they use parts that are commonly available. The steps taken to ease the ban is not aimed to protect Huawei but for preventing any harm to American companies.

The ban reportedly took place following the failure of talks to end the trade war between the United States and China, incited by allegations by the U.S. regarding Chinese corporate espionage, forced technology transfer and intellectual property theft.  Liang Hua, Huawei chairman said that Google, which sells software, hardware and technical services to Huawei, advocated to keep selling to the company.

A representative from the Commerce department said that the agency regularly responds to company’s inquiry concerning the scope for regulatory requirements.

Vice president of Public Affairs at Huawei, Andrew Williamson said that the companies lobbying against the ban are doing it by their own desire because Huawei is one of their major customers. Cutting of the Chinese giant would result in catastrophic consequences for them, Williamson added.

Source credits- https://in.reuters.com/article/huawei-tech-usa-lobbying/u-s-chipmakers-quietly-lobby-to-ease-huawei-ban-sources-idINKCN1TI07W

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...